Join Now

Author Archives: Natalie Themm

Halia Therapeutics Named as 2025 Top 10 Longevity Breakthrough Award Winner

Halia Therapeutics Named as 2025 Top 10 Longevity Breakthrough Award Winner

Posted in BioUtah News | Tagged | Comments Off on Halia Therapeutics Named as 2025 Top 10 Longevity Breakthrough Award Winner

Seek Labs Advances Development of Pan-Orthopoxvirus Therapeutic with BioSeeker™ and PTAP™

BioSeeker mapped more than 10,000 isolates and identified targetable regions that provide 100% strain coverage across the viral family.

Posted in BioUtah News | Tagged | Comments Off on Seek Labs Advances Development of Pan-Orthopoxvirus Therapeutic with BioSeeker™ and PTAP™

Biolexis Therapeutics Initiates First-in-Human Clinical Trials for Novel, Oral Muscle-Sparing, Weight Loss and Type 2 Diabetes Therapies

Biolexis Therapeutics Initiates First-in-Human Clinical Trials for Novel, Oral Muscle-Sparing, Weight Loss and Type 2 Diabetes Therapies

Posted in BioUtah News | Tagged | Comments Off on Biolexis Therapeutics Initiates First-in-Human Clinical Trials for Novel, Oral Muscle-Sparing, Weight Loss and Type 2 Diabetes Therapies

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

Posted in BioUtah News | Tagged | Comments Off on FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

2025 MedTech Conference Sponsored by AdvaMed

This week AdvaMed held its annual Medtech Conference, designed for those in the medical technology industry.

Posted in BioUtah News | Comments Off on 2025 MedTech Conference Sponsored by AdvaMed

Nelson Labs’ 40th Anniversary Celebration Recap

Nelson Labs on October 1 celebrated a milestone 40th anniversary. Since its humble beginnings in 1985 in University of Utah’s Research Park, Nelson Labs has grown into a trusted, global leader of medical device and pharmaceutical testing.

Posted in BioUtah News | Tagged | Comments Off on Nelson Labs’ 40th Anniversary Celebration Recap

Glafabra Therapeutics, Uncommon Cures Collaborate to Advance Fabry Disease Therapy

Glafabra Therapeutics, Uncommon Cures Collaborate to Advance Fabry Disease Therapy

Posted in BioUtah News | Tagged | Comments Off on Glafabra Therapeutics, Uncommon Cures Collaborate to Advance Fabry Disease Therapy

Seek Labs Selected as Participant of ARPA-H Investor Catalyst Hub Spoke Network, Rapid Response Partnership Vehicle

Seek Labs Selected as Participant of ARPA-H Investor Catalyst Hub Spoke Network and Rapid Response Partnership Vehicle (RRPV)

Posted in BioUtah News | Tagged | Comments Off on Seek Labs Selected as Participant of ARPA-H Investor Catalyst Hub Spoke Network, Rapid Response Partnership Vehicle

Innovative Wearable for Pelvic Floor Health by Freyya Completes Clinical Study

Innovative Wearable for Pelvic Floor Health by Freyya Completes Clinical Study

Posted in BioUtah News | Tagged | Comments Off on Innovative Wearable for Pelvic Floor Health by Freyya Completes Clinical Study

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

Posted in BioUtah News | Tagged | Comments Off on Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

Co-Diagnostics, Inc. Signs Strategic MOU with Partner in Kingdom of Saudi Arabia to Introduce Co-Dx™ PCR Platform to Middle East

The Memorandum of Understanding includes the formation of a Joint Venture in the Kingdom of Saudi Arabia for manufacturing and distribution of the Company’s upcoming Co-Dx™ PCR platform and other Co-Dx IP

Posted in BioUtah News | Tagged , | Comments Off on Co-Diagnostics, Inc. Signs Strategic MOU with Partner in Kingdom of Saudi Arabia to Introduce Co-Dx™ PCR Platform to Middle East

Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease

Definitive agreement to accelerate adoption of Renalytix’s FDA-approved, Medicare reimbursed kidneyintelX.dkd test to slow kidney disease progression and improve patient outcomes

Posted in BioUtah News | Tagged | Comments Off on Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease